<code id='BEA98D716A'></code><style id='BEA98D716A'></style>
    • <acronym id='BEA98D716A'></acronym>
      <center id='BEA98D716A'><center id='BEA98D716A'><tfoot id='BEA98D716A'></tfoot></center><abbr id='BEA98D716A'><dir id='BEA98D716A'><tfoot id='BEA98D716A'></tfoot><noframes id='BEA98D716A'>

    • <optgroup id='BEA98D716A'><strike id='BEA98D716A'><sup id='BEA98D716A'></sup></strike><code id='BEA98D716A'></code></optgroup>
        1. <b id='BEA98D716A'><label id='BEA98D716A'><select id='BEA98D716A'><dt id='BEA98D716A'><span id='BEA98D716A'></span></dt></select></label></b><u id='BEA98D716A'></u>
          <i id='BEA98D716A'><strike id='BEA98D716A'><tt id='BEA98D716A'><pre id='BEA98D716A'></pre></tt></strike></i>

          entertainment

          entertainment

          author:explore    Page View:1
          The FDA building -- First Opinion coverage from STAT
          Adobe

          WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

          Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

          advertisement

          To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Readout LOUD podcast: ALS dilemma, first MASH drug, and more
          Readout LOUD podcast: ALS dilemma, first MASH drug, and more

          Whathappenswhenanapproveddrugdoesn’twork?Whydon’tpatientswantgenetherapy?AndisMASHstillabigdeal?Weco

          read more
          What does generative AI mean for health care? We asked experts
          What does generative AI mean for health care? We asked experts

          MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

          read more

          Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

          Bayer'sU.S.president,SebastianGuth,emphasizedataninterviewattheSTATofficesinBostonthatthepharmacompa